Back to sleep: How SETD1A takes blood stem cells to rest

Jena, Germany. Stem cells are our body’s emergency reserve. In the blood system, so-called hematopoietic (blood) stem cells are responsible for continuously producing immune cells. This process, called hematopoiesis, is strictly regulated to make sure that the number of produced cells correlates to the actual need. However, every cell division also entails the risk of DNA damage accumulation that may result in loss of function and possibly even in cancerogenic transformation – the development of cancer. This is why stem cells usually rest in so-called quiescence to avoid attrition. During an infection, the number of immune cells needed is heavily rising, forcing blood stem cells to be activated in order to replicate and generate new immune cells. Subsequently, blood stem cells fall back to rest. In old organisms, this process is impaired because the accumulation of DNA damage increases over repeated cycling activity. Damaged cells are detected via a sensory system and are removed, which may result in the continuous reduction of the size of the available stem cell pool. So far, it was known that particular DNA repair pathways are necessary to repair DNA damages. However, it was totally unclear how DNA repair pathways are activated.

Together with other scientists from Dresden, Heidelberg and Berlin, Prof. Dr. Claudia Waskow – Senior Group Leader at Leibniz Institute on Aging (FLI) in Jena, Germany and at Technical University Dresden, Germany, holding a professorship at Friedrich Schiller University in Jena as well – and her team have identified an epigenetic mechanism, which in mice regulates the activation of the DNA damage response in blood stem cells and, thus, helps them back into their quiescence. Results have been published in Journal Blood.

SETD1A: An epigenetic sleeping aid

Biologist and aging researcher Waskow and her team found histone-3-lysine-4-methyletransferase SETD1A to regulate the activation of all known DNA repair pathways by means of a so-called epigenetic histone modification. These epigenetic switches work by adding defined molecular entities to particular gene segments, thus ‘marking’ this gene and making it available for being read. This is how SETD1A regulates whether gene segments, which are responsible for repairing DNA damages of blood stem cells, are activated or not. SETD1A was identified as the main driver of labeling the molecular groups and providing the whole repair machinery in blood stem cells, a process that is pivotal for the organism: In mice that lacked this genetic modifier, blood stem cells that had been activated during an infection, could not return to quiescence anymore. Blood stem cells accumulated DNA damages preventing the generation of mature immune cells, which resulted in a dramatically reduced survival rate after infection.

It may be possible to shorten the critical phase after infections

“The number of specific functions of SETD1A is really surprising”, explains Prof. Dr. Claudia Waskow. “Not only does SETD1A activity regulate the detection of DNA-damage in blood stem cells, but it also controls their repair. Simply spoken, SETD1A is crucial for the maintenance of blood stem cells”. If DNA damages in stem cells can be repaired fast and properly, they can go back to their resting phase more quickly, and further attrition can be avoided. This is how blood stem cells can be maintained to be available for reactivation during the next infection.

Since the repair mechanisms of SETD1A are based on epigenetic modifications, it may be possible to chemically control SETD1A activity. This can potentially provide a future approach for a supportive treatment after infections. “Especially in elderly people with a weaker immune system, the controlled increase of SETD1A activity could affect the return of blood stem cells back to quiescence in a positive way to maintain them for the next infection”, Prof. Waskow concludes.

Publication

Kathrin Arndt*, Andrea Kranz*, Juliane Fohgrub, Adrien Jolly, Anita S. Bledau, Michela Di Virgilio, Mathias Lesche, Andreas Dahl, Thomas Höfer, A. Francis Stewart and Claudia Waskow. SETD1A protects HSCs from activation-induced functional decline in vivo. Blood. 2018, 131(12), 1311-1324. doi: 10.1182/blood-2017-09-806844. (*equal contribution)

Contact

Dr. Kerstin Wagner
Press & Public relations
phone: +49 3641 656378
e-mail: presse@leibniz-fli.de
——————————-

Background information

The Leibniz Institute on Aging – Fritz Lipmann Institute (FLI) is the first German research organization dedicated to biomedical aging research since 2004. More than 330 members from over 30 nations explore the molecular mechanisms underlying aging processes and age-associated diseases. For more information, please visit .

The Leibniz Association connects 93 independent research institutions that range in focus from the natural, engineering and environmental sciences via economics, spatial and social sciences to the humanities. Leibniz Institutes address issues of social, economic and ecological relevance. They conduct knowledge-driven and applied basic research, maintain scientific infrastructure and provide research-based services. The Leibniz Association identifies focus areas for knowledge transfer to policy-makers, academia, business and the public. Leibniz Institutes collaborate intensively with universities – in the form of “WissenschaftsCampi” (thematic partnerships between university and non-university research institutes), for example – as well as with industry and other partners at home and abroad. They are subject to an independent evaluation procedure that is unparalleled in its transparency. Due to the institutes’ importance for the country as a whole, they are funded jointly by the Federation and the Länder, employing some 19,100 individuals, including 9,900 researchers. The entire budget of all the institutes is approximately 1.9 billion EUR. See for more information.

Scroll to Top